Vir Biotechnology (VIR) Set to Announce Earnings on Thursday

Posted by on Oct 26th, 2023

Vir Biotechnology (NASDAQ:VIR – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 2nd. Analysts expect Vir Biotechnology to post earnings of ($1.21) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.24). Vir Biotechnology had a negative net margin of 53.38% and a negative return on equity of 13.08%. The firm had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $22.39 million. During the same quarter in the previous year, the company earned ($0.58) EPS. The company’s quarterly revenue was up 379999900.0% compared to the same quarter last year. On average, analysts expect Vir Biotechnology to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Vir Biotechnology Stock Down 2.4 %

NASDAQ:VIR opened at $8.31 on Thursday. The company’s 50 day moving average price is $10.35 and its 200-day moving average price is $18.29. Vir Biotechnology has a 52 week low of $8.09 and a 52 week high of $31.55. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -4.22 and a beta of 0.27.

Analyst Ratings Changes

Several research analysts have weighed in on VIR shares. Morgan Stanley decreased their price target on shares of Vir Biotechnology from $27.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Friday, July 21st. Bank of America downgraded shares of Vir Biotechnology from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $23.00 to $14.00 in a research report on Friday, September 8th. The Goldman Sachs Group decreased their price objective on shares of Vir Biotechnology from $51.00 to $28.00 and set a “buy” rating on the stock in a research report on Friday, July 21st. Barclays decreased their price objective on shares of Vir Biotechnology from $59.00 to $41.00 and set an “overweight” rating on the stock in a research report on Friday, July 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Vir Biotechnology in a research report on Friday, August 4th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.11.

View Our Latest Analysis on VIR

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of VIR. Vanguard Group Inc. grew its position in Vir Biotechnology by 21.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,928,416 shares of the company’s stock worth $191,420,000 after purchasing an additional 1,731,172 shares during the last quarter. State Street Corp boosted its holdings in shares of Vir Biotechnology by 5.6% in the 3rd quarter. State Street Corp now owns 5,830,417 shares of the company’s stock valued at $112,410,000 after acquiring an additional 311,279 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Vir Biotechnology by 1.7% in the 1st quarter. BlackRock Inc. now owns 5,396,184 shares of the company’s stock valued at $138,790,000 after acquiring an additional 88,135 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Vir Biotechnology by 0.8% in the 4th quarter. Alliancebernstein L.P. now owns 2,353,859 shares of the company’s stock valued at $59,576,000 after acquiring an additional 19,541 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Vir Biotechnology by 10.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,690,777 shares of the company’s stock valued at $41,475,000 after acquiring an additional 165,359 shares during the last quarter. Institutional investors own 67.05% of the company’s stock.

Vir Biotechnology Company Profile

(Get Free Report)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Stories

Earnings History for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.